Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
7.10.2019 15:30:00 EEST | Business Wire | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1. Dr. Parsey will be responsible for the company’s global clinical development and medical affairs organizations. He will join the company’s senior leadership team and will report directly to Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. Under a new structure, William Lee, PhD, Gilead’s Executive Vice President, Research will separately report to Mr. O’Day.
Dr. Parsey joins Gilead from Genentech, Inc., a member of the Roche Group, where he currently holds the position of Senior Vice President, Early Clinical Development in the Genentech Research and Early Development (gRED) group. In this role, he leads clinical development, quality, compliance, informatics and clinical operations functions. He brings to Gilead significant clinical expertise across a broad array of therapeutic areas, including inflammation, oncology and infectious diseases.
“I am delighted to welcome Merdad, a seasoned and highly respected scientist, clinician and leader, to Gilead,” said Mr. O’Day. “Throughout his career, he has built a reputation as an outstanding leader among academic, industry and medical communities alike. I know Merdad’s exceptional skills and expertise will be of great benefit to Gilead as we focus on rapidly expanding our pipeline and clinical development portfolio through internal efforts and external partnerships.”
Prior to his most recent tenure with Genentech, Dr. Parsey served as President and CEO of 3-V Biosciences. He has also held development roles at Sepracor, Regeneron and Merck, Inc. and has served as Assistant Professor of Medicine and Director of Critical Care Medicine at New York University School of Medicine. Dr. Parsey completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.
“I have had many opportunities over the course of my career to help shape clinical development strategies and programs, and I am profoundly excited to bring those experiences to Gilead, an organization I have long admired,” said Dr. Parsey. “I am looking forward to working with the company’s talented teams to advance clinical development programs and build a robust pipeline that has the opportunity to change the trajectory of disease and transform the care of many more people in need around the world.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005221/en/
Contact information
Sung Lee, Investors
(650) 524-7792
Marni Kottle, Media
(650) 522-5388
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Identifies Ten Consumer Moments Reshaping Food and Beverage Innovation in the GLP-1 Era27.10.2026 17:00:00 EET | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, today launched its latest report, “GLP-1 Consumer Moments of Opportunity.” The report uncovers ten emerging consumer moments that reflect the changing needs of consumers using GLP-1 medications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026614988/en/ New report from IFF uncovers ten emerging consumer moments that reflect the changing needs of consumers using GLP-1 medications. “What GLP-1 users need from food and beverage products depends on the moment, and those needs can change many times throughout the day,” said Yuvraj Arora, president of IFF Taste. “The most successful innovations will be designed around the occasions that matter most to consumers, delivering the right balance of nutrition, enjoyment and functionality for each one. Understanding these moments can unlock entirely new avenues for innovation." While much of the indus
Phison Receives Micron Global Supplier Awards27.10.2026 16:00:00 EET | Press release
Phison Electronics (8299TT), a global leader in NAND flash controllers and storage solutions, is honored to announce that it was presented with Outstanding Supplier Performance Awards in the Semiconductor category and the Best in Quality – Assembly and Test categoryat the Micron Supplier Day 2026. The event, held in Boise, Idaho, United States was attended by top-level management of Micron and its suppliers, including Phison. The awards highlight our commitment to excellence in quality, innovation and collaboration with Micron, a global leader in semiconductor memory and storage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027158504/en/ Phison wins Outstanding Supplier Performance Award in Semiconductor category and the Best in Quality – Assembly and Test category at the Micron Supplier Day 2026 “Receiving our third Micron Supplier Award in a row is a tremendous honor and a testament to the strength of our partnership
Andersen Consulting Adds Collaborating Firm JKIT27.10.2026 15:30:00 EET | Press release
Andersen Consulting expands its digital and business transformation capabilities through a Collaboration Agreement with John Keells IT (JKIT), a Sri Lanka-based technology solutions provider. JKIT provides technology consulting and digital transformation services to organizations across multiple industries, including aviation, financial services, healthcare, manufacturing, retail, and telecommunications. The firm’s capabilities span enterprise applications, cloud transformation, cybersecurity, data and analytics, artificial intelligence, and intelligent automation. Leveraging strategic relationships with leading technology providers, including SAP, Microsoft, Salesforce, Databricks, and AWS, JKIT helps organizations modernize their technology infrastructure, streamline operations, strengthen decision-making, and drive business growth. “Organizations today are looking to accelerate their digital and AI transformation and need practical ways to translate innovation into measurable busine
MUFG Investor Services Appoints McAllister Kirschner Chief Executive Officer27.10.2026 15:15:00 EET | Press release
MUFG Investor Services today announced the appointment of McAllister (Mac) Kirschner as Chief Executive Officer, effective immediately. John Sergides has stepped down as Chief Executive Officer of MUFG Investor Services for health-related reasons. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027545977/en/ McAllister (Mac) Kirschner Appointed Chief Executive Officer of MUFG Investor Services Kirschner has served as Chief Operating Officer of MUFG Investor Services since 2018, overseeing business and banking operations across public and private markets. He joined MUFG Investor Services in 2016 and previously served as Global Head of Relationship Management, bringing extensive knowledge of the business, its clients, and operations. Before joining MUFG Investor Services, Kirschner was a Managing Director in BlackRock’s Global Fund Services business, where he led teams responsible for shareholder servicing, fund administrati
FEINDEF 27 Has Already Booked 94% of Its Exhibition Space Seven Months Ahead of the Event27.10.2026 15:03:00 EET | Press release
The International Defence and Security Exhibition of Spain (FEINDEF 27) has booked 94% of its exhibition space for 18 to 20 May 2027 at IFEMA Madrid, reflecting strong demand and interest among companies and institutions across the sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027170443/en/ Ángel Olivares, President of the Feindef Foundation Fundación Feindef announced the figure on Monday at the official presentation of the exhibition's fifth edition, held at Madrid's Rafael del Pino Auditorium. The fair is expected to cover more than 89,000 square metres, 46% more than in 2025. More than 746 exhibitors have been confirmed, up 19% on the previous edition. Of these, 37% are first-time participants and over 250 are international exhibitors, accounting for 33% of the total. The event will feature 14 international pavilions, strengthening its international reach as the defence and security industry gains prominence
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom